Polyclonal human IgG — Drug Target

All drugs that target Polyclonal human IgG — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Immunoglobulin replacement therapy

Phase 3 pipeline (2)

• IgPro20 (high dose) · CSL Behring · Immunoglobulin replacement therapy · Immunology
  IgPro20 is a subcutaneous immunoglobulin replacement therapy that provides passive immunity by delivering polyclonal human immunoglobulins to treat primary immunodeficiency.
• IgPro20 (low dose) · CSL Behring · Immunoglobulin replacement therapy · Immunology
  IgPro20 is a subcutaneous immunoglobulin replacement therapy that provides passive immunity by delivering polyclonal human immunoglobulins to patients with primary immunodeficiency.